Interview with Charles Woler, CEO, Endotis Pharma
Endotis was incorporated in 2003 on the basis of a technology transfer from on a French public research…
Address: 102 avenue Gaston Roussel
93230 Romainville France
Tel: +33 (0)1 48 46 43 91
Endotis Pharma is a biopharmaceutical company dedicated to the discovery and development of small-glyco drugs (SGDs, heparin / heparan sulphate mimetics) for use in thrombosis, oncology and a range of other indications with several potential blockbuster drugs. Founded in february 2003, Endotis is a privately held company which currently employs 34 people between sites in Paris and Lille.
Endotis’ business model is to develop antithrombotic drugs in man until proof-of principle (oral anticoagulants) or Phase IIb dose finding (parenteral antithrombotics), and then partner them; while in other therapeutic areas such as oncology, partnering could take place once proof of concept in animal is demonstrated.
Endotis has three main areas of activity:
– A derisked thrombosis franchise of heparin-derived synthetic oligosaccharides
– An oncology pipeline consisting of heparan sulfate mimetics
– A drug discovery engine: unique know-how from discovery to manufacturing of small-glyco drugs (SGDs) with range of applications
Endotis was incorporated in 2003 on the basis of a technology transfer from on a French public research…
While Big Pharma companies like Pfizer, Janssen and AstraZeneca, have grabbed the headlines over the past year for…
The latest from French pharma where Sanofi has inked a deal to produce 125 million doses of Pfizer’s COVID-19…
A roundup of the latest stories from French pharma, including the progress of Sanofi’s COVID-19 vaccine, how…
A roundup of some of the latest from French pharma, including Sanofi’s bumper Prinicipia deal, how Unither’s…
Sanofi has agreed a deal to buy out its partner, US biotech company Principia Biopharma for USD 3.7 billion in…
With former head David Loew moving to the CEO position at Ipsen, Sanofi appointed French national Thomas Triomphe…
French firm LFB is targeting the lucrative US market with its hemophilia products and recently received two FDA…
French pharma giant Sanofi is pivoting its focus to invest more heavily in vaccines with a plan to invest USD 679…
David Loew, formerly executive vice president of Sanofi Pasteur, Sanofi’s vaccines division, was appointed…
Emmanuel Macron and Angela Merkel recently put their heads together to come up with a health strategy that would…
In a recent interview with Financial Times, Sanofi CEO Paul Hudson set out to clarify some recent comments that the…
The world’s two leading vaccine producers, GSK of the UK and France’s Sanofi, last week announced that they are…